EverSource Wealth Advisors LLC Buys 2,431 Shares of Bristol-Myers Squibb (NYSE:BMY)

EverSource Wealth Advisors LLC boosted its stake in Bristol-Myers Squibb (NYSE:BMY) by 94.9% in the first quarter, HoldingsChannel reports. The firm owned 4,992 shares of the biopharmaceutical company’s stock after acquiring an additional 2,431 shares during the period. EverSource Wealth Advisors LLC’s holdings in Bristol-Myers Squibb were worth $271,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the stock. Hamilton Wealth LLC increased its holdings in Bristol-Myers Squibb by 106.3% in the first quarter. Hamilton Wealth LLC now owns 66,548 shares of the biopharmaceutical company’s stock valued at $3,609,000 after purchasing an additional 34,284 shares during the last quarter. Pathway Financial Advisers LLC bought a new stake in Bristol-Myers Squibb in the first quarter valued at about $60,000. Verity Asset Management Inc. increased its holdings in Bristol-Myers Squibb by 5.3% in the first quarter. Verity Asset Management Inc. now owns 6,212 shares of the biopharmaceutical company’s stock valued at $337,000 after purchasing an additional 315 shares during the last quarter. Cetera Advisors LLC grew its stake in Bristol-Myers Squibb by 122.3% in the first quarter. Cetera Advisors LLC now owns 270,340 shares of the biopharmaceutical company’s stock valued at $14,661,000 after acquiring an additional 148,729 shares during the period. Finally, Cetera Investment Advisers grew its stake in Bristol-Myers Squibb by 262.1% in the first quarter. Cetera Investment Advisers now owns 574,683 shares of the biopharmaceutical company’s stock valued at $31,165,000 after acquiring an additional 415,984 shares during the period. Institutional investors own 76.41% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have issued reports on BMY shares. StockNews.com raised Bristol-Myers Squibb from a “buy” rating to a “strong-buy” rating in a research note on Monday, July 29th. Barclays cut Bristol-Myers Squibb from an “overweight” rating to an “equal weight” rating and set a $41.00 target price for the company. in a research note on Monday, July 29th. Cantor Fitzgerald reissued a “neutral” rating and issued a $45.00 target price on shares of Bristol-Myers Squibb in a research note on Monday, July 22nd. Deutsche Bank Aktiengesellschaft decreased their target price on Bristol-Myers Squibb from $53.00 to $45.00 and set a “hold” rating for the company in a research note on Tuesday, July 23rd. Finally, Wells Fargo & Company upped their price objective on Bristol-Myers Squibb from $51.00 to $52.00 and gave the stock an “equal weight” rating in a research report on Thursday, April 18th. One equities research analyst has rated the stock with a sell rating, thirteen have given a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, Bristol-Myers Squibb has a consensus rating of “Hold” and an average target price of $55.79.

Bristol-Myers Squibb Stock Up 1.2 %

BMY traded up $0.60 during mid-day trading on Friday, reaching $48.77. 15,601,503 shares of the stock were exchanged, compared to its average volume of 17,378,216. The company has a 50 day moving average price of $42.39 and a two-hundred day moving average price of $46.73. The company has a debt-to-equity ratio of 2.86, a quick ratio of 0.99 and a current ratio of 1.16. The stock has a market capitalization of $98.88 billion, a PE ratio of -15.73, a price-to-earnings-growth ratio of 12.51 and a beta of 0.44. Bristol-Myers Squibb has a 1 year low of $39.35 and a 1 year high of $63.41.

Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings results on Friday, July 26th. The biopharmaceutical company reported $2.07 earnings per share for the quarter, topping analysts’ consensus estimates of $1.64 by $0.43. The company had revenue of $12.20 billion for the quarter, compared to the consensus estimate of $11.54 billion. Bristol-Myers Squibb had a negative net margin of 14.06% and a positive return on equity of 12.51%. The firm’s quarterly revenue was up 8.7% on a year-over-year basis. During the same period in the previous year, the firm earned $1.75 EPS. As a group, research analysts anticipate that Bristol-Myers Squibb will post 0.77 EPS for the current year.

Bristol-Myers Squibb Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Thursday, August 1st. Investors of record on Friday, July 5th were paid a $0.60 dividend. This represents a $2.40 dividend on an annualized basis and a yield of 4.92%. The ex-dividend date was Friday, July 5th. Bristol-Myers Squibb’s dividend payout ratio is currently -77.42%.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.